罚款22亿美元6月11日,强生买下一张沉甸甸的和解协议——支付22亿美元了结美国政府对精神病治疗药物Risperdal(维思通)和其他几款药物的非法营销调查。交完这笔罚款,这些药物在美国将不再超适应证使用。22亿美元对于强生来说不算重创,但加剧了其盈利水平走低的危机,强生再次陷入烦恼中。 Penalty $ 2.2 Billion On June 11, Johnson bought a heavy settlement agreement - paying $ 2.2 billion to settle the U.S. government’s illegitimate marketing investigation of psychotropic medication Risperdal and several other drugs. At the end of this fine, these drugs will no longer be used in the United States. The $ 2.2 billion is not a big hit for Johnson and Johnson but exacerbates the crisis of lower profitability and Johnson is again in trouble.